SEPTInvestingStart Free

HALO 8-K: Guidance raise

Halozyme

Filed with the SEC on · accession 0001159036-26-000143

HALO filed a 8-K (current report) with the SEC on Nov 5, 2026. Halozyme reported Q3 2026 results with total revenue up 39% YoY to $493 million and royalty revenue up 44% to $341 million, and raised its full-year 2026 financial guidance across revenue, EBITDA, and EPS. The stock moved -5.7% by the first close after the filing.

Summary of the filing

Halozyme reported Q3 2026 results with total revenue up 39% YoY to $493 million and royalty revenue up 44% to $341 million, and raised its full-year 2026 financial guidance across revenue, EBITDA, and EPS. The company also highlighted an expanded ENHANZE collaboration with three partners and a Dutch patent court injunction against Merck's Keytruda Qlex.

For details, click here →How to read a 8-K →

Key details

Q3 2026 total revenue$493.0M
Q3 2025 total revenue$354.3M
Q3 2026 royalty revenue$341.0M
Full year 2026 total revenue guidance low$1.9B
Full year 2026 total revenue guidance high$1.9B
Full year 2026 royalty revenue guidance low$1.2B
Full year 2026 royalty revenue guidance high$1.3B
Full year 2026 adjusted EBITDA guidance low$1.2B
Full year 2026 adjusted EBITDA guidance high$1.3B
Q3 2026 share repurchases$67.2M
2026 year-to-date share repurchases$400.0M
Convertible notes completed$1.5B
IssuerHalozyme Therapeutics, Inc.
Patent litigation defendantMerck & Co., Inc. / Merck Sharp & Dohme B.V.
Enhanze collaboration partnerargenx
Enhanze collaboration partnerIncyte
Enhanze collaboration partnerJohnson & Johnson / Janssen
Enhanze collaboration partnerPfizer
Enhanze collaboration partnerTakeda
Enhanze collaboration partnerRoche
Enhanze collaboration partnerGSK
President and chief executive officerDr. Helen Torley
Executive vice president and chief financial officerDarren Snellgrove

How HALO stock reacted

Close before

$130.34

Nov 4, 2026

First close after

-5.66%

$122.96

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for HALO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for HALO?

Click here

Frequently asked questions

What did HALO file with the SEC on Nov 5, 2026?

HALO filed a 8-K (Guidance raise). Halozyme reported Q3 2026 results with total revenue up 39% YoY to $493 million and royalty revenue up 44% to $341 million, and raised its full-year 2026 financial guidance across revenue, EBITDA, and EPS. The company also highlighted an expanded ENHANZE collaboration with three partners and a Dutch patent court injunction against Merck's Keytruda Qlex.

What does a guidance raise mean for HALO stock?

Guidance is the company’s own forecast. Investors price stocks on the future, so a raise or cut often moves the stock more than the past quarter’s numbers.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did HALO stock react to this filing?

HALO closed at $130.34 before the filing and $122.96 on Nov 5, 2026 (-5.66%).

Other HALO SEC filings

Get alerts when HALO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
HALO overviewHALO analysisHALO newsLatest SEC filings